Company: MYSZ
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001493152-25-023456
Chunk: 102

Company: My Size, Inc.
Filing Date: 2025-11-14
Form: 10-Q
Item: Part I, Item 1
Chunk 102
---
 RSUs granted during the nine-month period September 30, 2025, compared to an aggregate
of 91,875 options, shares of restricted common stock and RSUs granted during the nine-month period ended September 30, 2024, under the
Plan. No options were exercised.

On
June 4, 2025, the compensation committee of the Company’s board of directors reduced the exercise price of outstanding options
granted under the Plan of certain employees, officers and directors of the Company for the purchase of an aggregate of 13,926 shares
of common stock (with exercise prices ranging from $3.832 to $8.72 per share) to $1.28 per share, which was the closing price for the
Company’s common stock on June 4, 2025 (the “Option Repricing”). No options were exercised. In connection with the
Option Repricing, the Company accelerated the vesting options held by the Company’s former chief financial officer and the Company
recorded one-time expenses of $6 and $17.

The
total stock option compensation expense for employees during the nine and three-month period ended September 30, 2025 and 2024 was $84,
$16 and $235, and $214, respectively.

The
total stock option compensation expense relating to the Orgad acquisition during the nine and three-month period ended September 30,
2025 and 2024 was $0, $0, $3, and $0 respectively.

Options
issued to consultants:

In
July 2023, the Company entered into a six month agreement (the “Consultant Agreement”) with a consultant (the “Consultant”)
to provide services to the Company, including assisting the Company to promote, market and sell the Company’s technology to potential
customers and make strategic introductions and inquiries with interested parties in the financial community. Pursuant to the Consultant
Agreement and in partial consideration for such consulting services, the Company issued to the Consultant (i) 5,000 shares of restricted
common stock of the Company, (ii) a warrant to purchase 12,500 shares of common stock at an exercise price of $4.00 per share and exercisable
for a term of 36 months from the date of issuance, and (iii) a warrant to purchase 12,500 shares of common stock at an exercise price
of $6.00 per share and exercisable for a term of 36 months from the date of